s The stability of solvent-resistant nanofiltration (SRNF) membranes, such as integrally skinned asymmetric (ISA) and thin-film composite (TFC) membranes, in polar aprotic solvents must be improved if they are to meet increasingly complex industrial demands. The stability of the former membranes can be improved by forming crosslinked rigid chains, such as polybenzimidazoles and polyimides, but this requires time-consuming treatment processes. Conversely, the latter membranes are easy to fabricate but lack efficient active sites for crosslinking and structural rigidity. Herein, we present a fabrication strategy combining the characteristics of both types of membranes. We first utilize amino-functional porphyrins as polyaromatic units to form rigid polyamide networks by vacuum-assisted interfacial polymerization, simultaneously providing active sites for further crosslinking, which is accomplished by immersion in FeCl 2 /dimethyl sulfoxide (DMSO) solution to directly establish Fe-O-Fe bridges between porphyrin centers to form a stable network. The Fe-O-Fe-bridged porphyrin networks are solvent-stable in DMSO. Furthermore, they achieve outstanding molecular separation (96.2% rejection of methyl orange, 327 Da) and limited molecular-weight-cutoff change (from 360 to 420 Da) during alternating MeOH and DMSO filtration, along with long-term recovery efficiency (> 96.7% over seven days). Thus, our study provides a promising strategy for the facile development and fabrication of efficient, robust SRNF membranes.
Dafa Yi,Jiazong Ye,Zebei Lu,Leilei Lu,Tengfei Qi,Tong Luo,Xiuyun Peng,Abdullah Al Mamun,Quan Zhou,Daqing Chen,Shuanghu Wang
This study investigates the potential drug-drug interactions between commonly prescribed anti-hypertensive drugs and mobocertinib in clinical practice to provide the scientific basis for the appropriate therapeutic application of drugs. The study used UPLC-MS/MS to detect the essential metabolites of mobocertinib in rat liver microsomes. Moreover, several anti-hypertensive drugs were used as inhibitors and the IC 50 values were determined for calcium channel blockers, angiotensin II receptor blockers and α and β receptor blockers against mobocertinib. The inhibitory mechanism of mobocertinib was further investigated for nicardipine, irbesartan, telmisartan, carvedilol, prazosin hydrochloride and spironolactone. Twenty-five Sprague Dawley ( SD) rats were randomly divided into five groups: benidipine, nicardipine, telmisartan, irbesartan and blank control groups. The drugs were administered over a period of 7 days. Mobocertinib was administered once by gavage to five groups and then blood samples were collected for further analysis. UPLC-MS/MS was performed to analyze the concentration of mobocertinib and its metabolites in rat plasma. Most anti-hypertensive drugs were found to inhibit the metabolism of mobocertinib in vitro. Several anti-hypertensive drugs were also found to increase the plasma concentration and decrease the metabolic rate of mobocertinib when administered multiple times. More importantly, we found that benidipine, nicardipine, telmisartan and irbesartan inhibited the metabolism of mobocertinib in vitro and in vivo . In summary, our data reveal that anti-hypertensive drugs interact with mobocertinib and additional attention is needed when co-administering the two drugs.
危险品化学品经营许可证（带存储）